Hyponatremia: a case report of SIAD

Hyponatremia: a case report of SIAD

Authors

  • Letizia Canu Dipartimento di Scienze Biomediche Sperimentali e Cliniche, Unità di Endocrinologia, AOU Careggi, Università degli Studi di Firenze
  • Alessandro Peri Dipartimento di Scienze Biomediche Sperimentali e Cliniche, Unità di Endocrinologia, AOU Careggi, Università degli Studi di Firenze
  • Gabriele Parenti DAI Biomedicina, SOD. Endocrinologia, AOU Careggi, Firenze

DOI:

https://doi.org/10.7175/cmi.v7i2.640

Keywords:

Hyponatremia, SIAD, Fluid restriction, Vaptans

Abstract

Hyponatremia, defined as serum sodium concentration <136 mEq/l, represents one of the most frequently encountered electrolyte disorder in clinical practice. Among hospitalised patients up to 15-30% present mild hyponatremia (130-135 mEq/l), whereas moderate to severe forms are seen in up to 7% of inpatients. Hyponatremia is associated with significant morbidity and mortality especially in patients with underlying diseases. According to volume status hyponatremia can be classified as hypovolemic, hypervolemic or euvolemic. An accurate diagnostic algorithm has to be performed in order to optimize the therapeutic approach. Acute and severe forms are accompanied by neurological symptoms due to cerebral edema and can cause death if not appropriately treated. Moreover, even a too rapid correction can be associated with serious complications, such as the osmotic demyelination syndrome. Hypovolemic forms have to be treated with isotonic saline infusion, whereas eu-hypervolemic forms require hypertonic saline when symptomatic, and fluid restriction or vaptans when asymptomatic. Here, we report the case of a 79-year-old woman with hyponatremia admitted to the Emergency Department of XXX.

References

Hoorn EJ, Lindemans J, Zietse R. Development of severe hyponatremia in hospitalized patients: treatment-related risk factors and inadequate management. Nephrol Dial Transplant 2006; 21: 70-6. http://dx.doi.org/10.1093/ndt/gfi082

Renneboog B, Musch W, Vandemergel X, et al. Mild chronic hyponatremia is associated with falls, unsteadiness and attention deficits. Am J Med 2006; 119: 71. http://dx.doi.org/10.1016/j.amjmed.2005.09.026

Gankam KF, Andres C, Sattar L, et al. Mild hyponatremia and risk of fracture in the ambulatory elderly. QJM 2008; 101: 583-8. http://dx.doi.org/10.1093/qjmed/hcn061

Kinsella S, Moran S, Sullivan MO, et al. Hyponatremia independent of osteoporosis is associated with fracture occurrence. Clin J Am Soc Nephrol 2010; 5: 275-80. http://dx.doi.org/10.2215/CJN.06120809

Verbalis JG, Barsony J, Sugimura Y, et al. Hyponatremia-induced osteoporosis. J Bone Miner Res 2010; 25: 554-63. http://dx.doi.org/10.1359/jbmr.090827

Barsony J, Sugimura Y, Verbalis JG. Osteoclast response to low extracellular sodium and the mechanism of hyponatremia-induced bone loss. J Biol Chem 2011; 286: 10864-75. http://dx.doi.org/10.1074/jbc.M110.155002

Adroguè HJ, Madias NE. Hyponatremia. N Eng J Med 2000; 342; 1581-9

Baylis PH. The syndrome of inappropriate antidiuretic hormone secretion. Int J Biochem Cell Biol 2003; 35: 1495-9. http://dx.doi.org/10.1016/S1357-2725(03)00139-0

Cowtan T. Thiazide diuretics. N Eng J Med 2010; 362: 659-60. http://dx.doi.org/10.1056/NEJMc0912839

Saito T, Ishikawa SE, Ando F, et al. Vasopressin-dependent upregulation of aquaporin-2 gene expression in glucocorticoid-deficient rats. Am J Physiol Renal Physiol 2000; 279: F502-8

Karthik S, Roop R, Mediratta NK. Adenocarcinoma of lung presenting with dysgeusia. Thorax 2004; 59: 81-4. http://dx.doi.org/10.1136/thx.2004.001479

Reddy P, Mooradian AD. Diagnosis and management of hyponatremia in hospitalize patients. Int J Clin Pract 2009; 63: 1494-1508. http://dx.doi.org/10.1111/j.1742-1241.2009.02103.x

Vaidya C, Warren HO, Freda BJ. Management of hyponatremia: providing treatment and avoiding harm. Clev Clin J Med 2010; 77: 715-26

Sterns RH, Cappuccio JD, Silvver SM, et al. Osmotic demyelination syndorme following correction of hyponatremia. N Eng J Med 1986; 314: 1535-42

Hannon MJ, Thompson CJ. The syndrome of inappropriate antidiuretic hormone: prevalence, causes anc consequences. Eur J Endocrinol 2010; 162: S5-12. http://dx.doi.org/10.1530/EJE-09-1063

Peri A, Pirozzi N, Parenti G et al. Hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone (SIADH). J Endocrinol Invest 2010; 33: 671-82

Feldman BJ, Rosenthal SM,Vargas GA, et al. Nephrogenic syndrome of inappropriate antidiuresis. N Eng J Med 2005; 352: 1884-90. http://dx.doi.org/10.1056/NEJMoa042743

Verbalis JG, Goldsmith SR, Greenberg A, et al. Hyponatremia treatment guidelines 2007: expert panel recommendations. Am J Med 2007; 120: S1-21. http://dx.doi.org/10.1016/j.amjmed.2007.09.001

Furst H, Hallows KR, Post J, et al. The urine/plasma electrolyte ratio: a predictive guide to water restriction. Am J Med Sci 2000; 319: 240-4. http://dx.doi.org/10.1097/00000441-200004000-00007

Udelson JE, Smith WB, Hendrix GH, et al. Acute hemodynamic effects of conivaptan, a dual V(1A) and V(2) vasopressin receptor antagonist, in patients with advanced hearth failure. Circulation 2001; 104: 2417-23. http://dx.doi.org/10.1161/hc4501.099313

Schrier RW, Gross P, Gheorghiade M, et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Eng J Med 2006; 355: 2099-112

Konstam MA, Gheorghiade M, Burnett JC Jr, et al. Effects of oral tolvaptan in patients hospitalized for worsening hearth failure: the EVEREST outcome trial. JAMA 2007; 297: 1319-31. http://dx.doi.org/10.1001/jama.297.12.1319

Berl T, Quittnat-Pelletier F, Verbalis JG, et al. Oral tolvaptan is safe and effective in chronic hyponatremia. J Am Soc Nephrol 2010; 21: 705-712. http://dx.doi.org/10.1681/ASN.2009080857

Verbalis JG, Adler S, Schrier RW, et al. Efficacy and safety of oral tolvaptan therapy in patients with the syndrome of inappropriate antidiuretic hormone secretion. Eur J Endocrinol 2011; 164: 725-732. http://dx.doi.org/10.1530/EJE-10-1078

Downloads

Published

2013-06-25

Issue

Section

Case report
Loading...